What Maxilase Treats: Main Uses and Benefits

Maxilase is commonly used as an adjunctive therapy for conditions involving inflammatory or irritative processes. Its primary purpose is to provide symptomatic support for the physical discomfort associated with acute, localized tissue changes.

The medication is generally applied in clinical contexts where patients experience symptoms related to physical discomfort, such as minor sore throat that is not associated with fever. It is relevant for conditions presenting with acute episodes, including acute pharyngitis and tonsillitis. It is applied in contexts where additional symptomatic support is needed for congestive states of the oropharynx, based on its established therapeutic indication.

It is applied in addressing symptom clusters that may become intense or disruptive, particularly those creating noticeable functional strain, like difficulty or pain when swallowing. This supportive role contributes to improved day-to-day comfort during periods of heightened symptoms.

Quick Fact: Focus: Symptomatic Relief for Localized Swelling It is used in areas where short-term symptom management is appropriate for localized tissue swelling and the resulting congestion within the mouth and throat area.

Regulatory References

1. Base de Données Publique des Médicaments (ANSM) notice

Who Can and Cannot Use Maxilase?

This section outlines the officially documented population eligibility rules for using Maxilase (Alpha-amylase), based strictly on governmental regulatory labeling. Eligibility is determined by age, medical status, and the presence of hypersensitivity.

---

Contraindications and Restrictions

Maxilase is contraindicated and must not be used by individuals with a history of allergy or hypersensitivity to the active substance, Alpha-amylase, or any of the medicine’s excipients. This constitutes an absolute exclusion from use.

---

Age-Specific Eligibility

Use is defined by the patient's age and the specific formulation:

• Adults are eligible for both the coated tablet and syrup formulations.
• Pediatric Use: The syrup form has established use for infants from 6 months of age (and ge 7 kg) and children. The coated tablet formulation is typically reserved for adults and is generally not suitable for children under 6 years.

---

Conditional Use Status

Official labeling indicates specific populations should avoid or for whom use is not recommended:

• Pregnancy and Lactation: The medicine is officially not recommended during pregnancy and should be avoided during breastfeeding due to insufficient regulatory data.
• Hereditary Intolerances: Use is not recommended for patients with rare hereditary sugar intolerances, such as fructose intolerance or glucose/galactose malabsorption, due to the presence of specific excipients in the product.

Official Documented Interaction Profile

The official interaction profile for Maxilase (Alpha-amylase) is characterized by the explicit regulatory declaration concerning the availability of formal interaction data. According to government prescribing information, no specific interaction studies have been formally performed to evaluate potential pharmacokinetic or pharmacodynamic interactions with other medicinal products.

Drug–Drug Interaction Status

As a direct result of this regulatory status, official product labeling does not list any specific interacting medicinal products that require restricted use, dose adjustment, or co-administration prohibitions. Regulatory documents confirm that no mechanistic basis, such as inhibition or induction of cytochrome P450 (CYP) enzymes or drug transporters (e.g., P-gp), is formally documented for Alpha-amylase interactions. Furthermore, official documentation does not contain any mandatory timing-based administration rules for Maxilase separation from other treatments.

Interactions with Food and Other Substances

Maxilase's interaction profile with non-medicinal substances is also defined in regulatory records. Interactions with food, drink, alcohol, herbal products, or dietary supplements are formally stated as "Not applicable" in the official prescribing information for the active substance. No population-specific interaction considerations (e.g., related to hepatic impairment) are documented in the context of drug–drug interactions. This entire framework constitutes the complete, documented interaction structure as defined by governmental health authorities.

Modulating Tissue Fluid Dynamics via Enzymatic Action

Alpha-amylase exerts its action through the enzymatic hydrolysis of components in the inflammatory exudate. This action is confined to the specific macromolecules and fluid that leak into tissue spaces during the acute inflammatory process. The enzyme, Alpha-amylase, directly targets the macromolecular components—primarily protein aggregates and polysaccharides—that accumulate in the interstitial fluid (exudate) outside the microvasculature. By acting as a catalyst, the enzyme breaks down these large molecules into smaller fragments. This core mechanistic cascade is classified as an anti-oedematous action because its functional consequence is the modulation of the tissue's physical fluid dynamics.

---

Accelerating Clearance of Localized Exudate

The hydrolysis of macromolecules significantly reduces the local osmotic pressure within the tissue space. This pressure differential alters the balance of fluid exchange, supporting the reabsorption of interstitial fluid and protein back into the circulation. The resultant physiological effect is the accelerated clearance of interstitial fluid, which reduces the volume and tension within the affected tissue. The mechanism is therefore constrained to the peripheral and acute exudative phase of inflammation.

Maxilase is utilized through the oral route of administration. The usage protocol is structured around two principal formulations: a coated tablet containing 3000 U. CEIP of Alpha-amylase, and a syrup solution with a concentration of 200 U. CEIP/ml.

Administration Schedule and Constraints

The dosing regimen is based on a fixed frequency and administration timing, designed to maintain a consistent use pattern.

Usage Parameter	Description
Route of Administration	Oral intake only.
Standard Adult Frequency	Three times daily (3 doses per 24 hours).
Timing	Tablets must be administered during meals (au cours des repas).
Intake Condition	Tablets must be swallowed whole (sans les croquer) with water; they should not be crushed or chewed.

Dosing Protocol and Duration

Distinct dosing rules are established based on age and weight, alongside a strict limit on the course duration.

The 3000 U. CEIP tablet is reserved for adult use. For adults, the standard dose is one tablet or one 15 ml tablespoon of the syrup, three times per day. The syrup formulation is adapted for pediatric groups, with doses tiered to the child's weight/age: 5 ml (1 teaspoon) for infants and children between 6 months and 3 years (7–15 kg), and 10 ml (2 teaspoons) for children over 3 years old (> 15 kg).

A critical constraint is the time-limited use. Administration is stipulated not to exceed 5 days; if symptoms persist after this period, further medical assessment is required.

Research Evidence / Overview of Studies for Maxilase

Evidence for Use in Acute Oropharyngeal Inflammation

The enzyme Alpha-amylase was evaluated in research exploring its potential use as an adjunctive measure for conditions associated with acute or disruptive episodes of localized inflammation in the throat, such as pharyngitis or mild sore throat. The evidence base includes older Randomized Controlled Trials (RCTs) and supporting pharmacological studies that examined the enzyme's association with localized swelling. Studies monitored outcomes related to inflammatory or irritative states, focusing on short-term symptom changes observed during the study period. Regulatory authorities rely on this existing evidence base, which contributes to the broader evidence landscape for symptomatic support in these acute settings.

---

What Research Examined in Clinical Studies

Studies explored how symptoms evolved in the observed populations by measuring patient-reported outcomes describing perceived discomfort. Research examined outcomes related to physical discomfort and functional measures, such as difficulty or pain when swallowing, which are common complaints during periods of heightened symptom activity. Findings from this research describe short-term changes and findings help contextualize how patients reported their experience during the study.

---

Evidence Gaps, Duration, and Special Populations

Clinical evaluations for Maxilase was evaluated in a range of patient groups, including both Adults and Children (aged 6 months and older). However, the follow-up durations were limited to the typical expected length of an acute episode, often spanning just a few days. Consequently, there is limited information for long-term outcomes or data regarding the recurrence rates of throat inflammation. The research landscape shows that evidence quality varies across studies, and contemporary, high-quality comparative evidence is lacking for the specific Maxilase formulation against other treatments. Certainty remains low due to these identified research limitations.

Key Studies & References

1. Official Public Database of Medicines Notice (ANSM) - Maxilase (Alpha-amylase)
2. WHO Anatomical Therapeutic Chemical (ATC) Classification System - Alpha-amylase

How to Store and Dispose of Maxilase

Official regulatory guidance specifies distinct maximum storage temperatures for Maxilase (Alpha-amylase) based on its dosage form. The Syrup formulation must be stored at a temperature that does not exceed 25 C. The Tablet formulation must be stored at a temperature below 30 C.

All forms of this medicine must be kept out of the sight and reach of children. Maxilase must be stored in its original outer packaging; the liquid form should also be kept tightly closed to maintain product stability.

For disposal, unused or expired Maxilase must not be discarded via household waste or poured into wastewater. Medicines must be returned to a pharmacist or an approved local collection program for proper environmental handling.